CA3190109A1 - Formulations d'anticorps anti-integrine beta7 et dispositifs - Google Patents

Formulations d'anticorps anti-integrine beta7 et dispositifs

Info

Publication number
CA3190109A1
CA3190109A1 CA3190109A CA3190109A CA3190109A1 CA 3190109 A1 CA3190109 A1 CA 3190109A1 CA 3190109 A CA3190109 A CA 3190109A CA 3190109 A CA3190109 A CA 3190109A CA 3190109 A1 CA3190109 A1 CA 3190109A1
Authority
CA
Canada
Prior art keywords
hvr
formulation
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3190109A
Other languages
English (en)
Inventor
Jennifer PULLEY
Meina Tao TANG
Swati TOLE
Helen TYRRELL
Mariam ABOUHOSSEIN
Hemanth AMARCHINTA
Audrey BORUVKA
Han Ting Ding
Heather L. FLORES
Glen Scott GIESE
Renato Ravanello
Wenhui Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Genentech Inc filed Critical F Hoffmann La Roche AG
Publication of CA3190109A1 publication Critical patent/CA3190109A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des formulations comprenant un anticorps anti-intégrine bêta7 ou un fragment de liaison à l'antigène associé, notamment des formulations pharmaceutiques. L'invention concerne également un article manufacturé comprenant de telles formulations, et des méthodes d'utilisation de telles formulations.
CA3190109A 2020-07-31 2021-07-29 Formulations d'anticorps anti-integrine beta7 et dispositifs Pending CA3190109A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063059427P 2020-07-31 2020-07-31
US63/059,427 2020-07-31
PCT/US2021/043690 WO2022026699A1 (fr) 2020-07-31 2021-07-29 Formulations d'anticorps anti-intégrine bêta7 et dispositifs

Publications (1)

Publication Number Publication Date
CA3190109A1 true CA3190109A1 (fr) 2022-02-03

Family

ID=77693570

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3190109A Pending CA3190109A1 (fr) 2020-07-31 2021-07-29 Formulations d'anticorps anti-integrine beta7 et dispositifs

Country Status (11)

Country Link
EP (1) EP4188958A1 (fr)
JP (1) JP2023536158A (fr)
KR (1) KR20230041071A (fr)
AR (1) AR123085A1 (fr)
AU (1) AU2021316017A1 (fr)
BR (1) BR112023001734A2 (fr)
CA (1) CA3190109A1 (fr)
IL (1) IL300133A (fr)
MX (1) MX2023001157A (fr)
TW (1) TW202222832A (fr)
WO (1) WO2022026699A1 (fr)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993006217A1 (fr) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION DANS L'E. COLI DE FRAGMENTS D'ANTICORPS POSSEDANT AU MOINS UNE CYSTEINE PRESENTE SOUS FORME D'UN THIOL LIBRE, ET LEUR UTILISATION DANS LA PRODUCTION D'ANTICORPS BIFONCTIONNELS F(ab')¿2?
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE387495T1 (de) 1996-12-03 2008-03-15 Amgen Fremont Inc Vollkommen humane antikörper die egfr binden
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ATE303445T1 (de) 1999-10-04 2005-09-15 Medicago Inc Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
DK1324776T4 (en) 2000-10-12 2018-05-28 Genentech Inc CONCENTRATED PROTEIN FORMULATIONS WITH REDUCED VISCOSITY
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
RS57636B1 (sr) 2004-09-03 2018-11-30 Genentech Inc Humanizovani anti-beta7 antagonisti i njihova upotreba
SI2279004T1 (sl) 2008-05-16 2015-05-29 F. Hoffmann-La Roche Ag Uporaba biomarkerjev za ocenjevanje zdravljenja gastrointestinalnih vnetnih motenj z antagonisti beta7 integrina
KR20110128333A (ko) 2009-03-06 2011-11-29 제넨테크, 인크. 항체 제제
MX367097B (es) * 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
CA2839493C (fr) 2011-06-17 2016-02-09 Shl Group Ab Dispositif d'injection
US9132236B2 (en) 2011-06-17 2015-09-15 Shl Group Ab Injection device
CN105143876B (zh) 2013-03-27 2018-04-20 豪夫迈·罗氏有限公司 生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途
CN113604543A (zh) 2014-03-27 2021-11-05 豪夫迈·罗氏有限公司 用于诊断和治疗炎症性肠病的方法
EP3262072A1 (fr) * 2015-02-26 2018-01-03 F. Hoffmann-La Roche AG Antagonistes d'intégrine bêta7 et procédés de traitement de la maladie de crohn
WO2019246455A1 (fr) * 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal par un inhibiteur de l'intégrine

Also Published As

Publication number Publication date
EP4188958A1 (fr) 2023-06-07
KR20230041071A (ko) 2023-03-23
IL300133A (en) 2023-03-01
AR123085A1 (es) 2022-10-26
MX2023001157A (es) 2023-02-22
JP2023536158A (ja) 2023-08-23
TW202222832A (zh) 2022-06-16
WO2022026699A1 (fr) 2022-02-03
AU2021316017A1 (en) 2023-02-16
BR112023001734A2 (pt) 2023-02-28

Similar Documents

Publication Publication Date Title
US20210322546A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
US11560434B2 (en) Formulation for anti-α4β7 antibody
KR102259829B1 (ko) 항체 제제
KR101841527B1 (ko) 개선된 고농도 항－ＴＮＦα 항체 액체 제형
KR101540823B1 (ko) 항체 제제
JP7277649B2 (ja) 高濃度抗ｃ５抗体製剤
US20210040222A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
US20130315913A1 (en) Anti-light antibody therapy for inflammatory bowel disease
CA3190109A1 (fr) Formulations d'anticorps anti-integrine beta7 et dispositifs
JP7343547B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
WO2021207667A1 (fr) Compositions et méthodes de traitement de lésion pulmonaire ou de syndrome de détresse respiratoire aiguë (sdra)
US20240141051A1 (en) Methods for treating hand and foot dermatitis by administering an il-4r antagonist
KR20230004489A (ko) 아토피 피부염 및 관련 장애의 치료 방법
TW202317184A (zh) 用於治療異位性皮膚炎和相關障礙之方法
EP4382164A2 (fr) Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste de l'il-4r
NZ617340B2 (en) Formulation for anti-?4?7 antibody